Milax

Quick links to important sections

Milax

Method of action: Laxative

Treatment option: Sore Throat, Constipation

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Milax

Quick Facts

Property Description
Active ingredient Glycerol (Propane-1,2,3-triol)
Form Rectal Suppository
Pharmacological class Osmotic Laxative
Common use Relief of occasional constipation
Origin Synthetic

What Type of Medicine is Milax?

Milax is a pharmaceutical preparation classified as an Osmotic Laxative, the primary purpose of which is to provide effective relief from occasional constipation. The medicinal entity contains the single active ingredient, Glycerol, which is recognized for its use in various pharmaceutical formulations. This classification is based on its fundamental action, where the substance draws water into the colon rather than chemically stimulating the bowel or adding indigestible bulk, defining it as a localized physical agent. Glycerol has been clinically recognized for its utility in this context for both adult and pediatric patient groups.

This high-level pharmacological classification places it separately from other types of relief preparations, such as stimulant laxatives, ensuring its mechanism operates on a different principle of hydrating the stool mass. The preparation's status as an Over-the-Counter (OTC) agent highlights its established suitability for the temporary management of simple constipation.

Composition, Form, and Origin (Glycerol Suppository)

The definitive dosage form of this preparation is the Rectal Suppository, which delivers the Glycerol directly to the lower gastrointestinal tract, ensuring focused and immediate local effect. The active ingredient, while a naturally occurring trivalent alcohol, is typically derived through controlled industrial, synthetic processes to ensure the requisite pharmaceutical purity and consistent concentration. This specific suppository form is composed of the Glycerol substance suspended in a solid base, such as hard fat or other glycerides, which melts at body temperature.

This direct rectal route and solid-base composition distinguishes it from systemic medications, ensuring its activity is localized and highly efficient for addressing impaction in the lower bowel, which is a key differentiating factor from orally administered osmotic agents.

How the Glycerol Component Provides General Relief

Glycerol provides relief from hardened stools by utilizing a hyperosmotic effect, meaning it acts as a magnet to draw and retain water from the surrounding tissues into the rectal lumen. This influx of fluid serves two functions: it significantly softens the stool mass and concurrently provides essential lubrication to the lower bowel wall. The combined action assists the body in facilitating the natural expulsion of the stool, contributing to the general purpose of alleviating constipation, a typical use scenario when a quick, localized intervention is desired. This class of medicine is utilized to help stool pass more easily by ensuring it retains adequate fluid.

Regulatory References

  1. MedlinePlus Polyethylene Glycol Drug Information

What side effects are possible with Milax?

Possible Side Effects and Safety Information

The official safety profile for Milax (Glycerol Suppository) focuses primarily on localized reactions due to its direct action in the lower gastrointestinal tract. Regulatory documents classify the officially listed adverse effects under Gastrointestinal Disorders and General Disorders and Administration Site Conditions.

Specific side effects explicitly listed in regulatory labeling include rectal discomfort, rectal irritation, and a burning sensation at the site of administration. Some individuals may also experience localized abdominal discomfort or cramping.


Key Safety Constraints and Considerations

While serious adverse reactions are not commonly cited in the general regulatory labeling for this type of over-the-counter medicine, certain high-level safety constraints are documented:

  • Duration-Related Pattern: A key consideration in the official safety notes is the risk of developing laxative dependence or tolerance. This occurs only when the medicine is used excessively or for a prolonged period beyond the management of occasional constipation.
  • Pre-Existing Symptoms: The preparation is officially restricted for use when acute abdominal symptoms, such as abdominal pain, nausea, or vomiting, are already present before administration.
  • Population-Specific Confirmation: The safety profile is confirmed in official documents for use in pediatric patients aged 2 years and older, with no distinct adverse effect profile noted compared to adults.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Milax (Glycerol Suppository) confirms that an overdose is unlikely to occur when the product is administered via the intended rectal route. This conclusion is based on the localized action of the suppository in the lower gastrointestinal tract.

The primary focus of overdose guidance addresses the rare event of acute accidental oral ingestion (swallowing) of the product. Documented systemic manifestations associated with the swallowing of a large number of suppositories include headache, dizziness, mental confusion, nausea, and diarrhoea. Severe outcomes officially described in the labeling include the potential for cardiac arrhythmias, trouble breathing, or passing out (loss of consciousness).

Emergency Actions and Help-Seeking Requirements

Regulatory documents mandate specific actions if accidental ingestion occurs. Users must seek immediate medical help and contact a Poison Control Center right away if the product is swallowed. For severe or life-threatening manifestations, such as trouble breathing or passing out, users must immediately call emergency services. The officially required management procedure for ingestion is to treat symptomatically. Furthermore, medical advice must be sought if rectal bleeding or no bowel movement is experienced after use, as these symptoms may indicate a serious underlying condition. No specific antidote is listed in the official prescribing information.

Therapeutic Uses of Milax

What Milax Treats: Main Uses and Benefits

Milax (Glycerol Suppository) is used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. It is commonly used to help with short-term management of acute discomfort and symptoms that interfere with daily functioning in the lower bowel. It helps address symptom clusters that may become intense or disruptive, such as straining, difficult passage of stools, and the feeling of rectal fullness.

The preparation is commonly used to help with symptoms related to occasional constipation.

Contexts and Benefits

This preparation plays a role in managing symptoms linked to lower bowel impaction and acute, temporary bowel retention resulting from situational factors such as changes in diet or restricted activity. It is applied when short-term symptomatic assistance is needed to resolve the sudden episode of infrequent and incomplete movements. It is relevant in contexts involving heightened systemic burden, such as when temporary assistance for symptom stabilization is needed before certain medical procedures.

“It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.”

This supportive relief provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.

Quick Fact: Relief for Constipation
Primary Use Focus Occasional and Acute Constipation
Symptom Addressed Difficult Passage of Stools, Straining
Common Scenario Situational needs (e.g., travel, restricted mobility)

Regulatory References

  1. DailyMed overview from the National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Milax (polyethylene glycol 3350) is an osmotic laxative used to relieve occasional constipation. However, specific health conditions and age groups must follow eligibility guidelines established in official regulatory labeling.

Contraindications and Restrictions

Classification Condition/Population Restriction Type
Contraindicated Known or suspected bowel obstruction (intestinal blockage). Do Not Use
Known allergy or hypersensitivity to polyethylene glycol 3350. Do Not Use
Caution Required Kidney disease (renal impairment). Use not recommended except under a doctor's supervision.
Nausea, vomiting, or severe stomach pain (may indicate a more serious condition). Consult a doctor before use.
Sudden change in bowel habits lasting over two weeks. Consult a doctor before use.

Age and Physiological States

  • Children 16 years of age and under: Use and dosage must be determined by a healthcare provider, as safety and effectiveness in this population are not formally established for over-the-counter use.
  • Adults 17 years of age and older: Eligible for standard use for occasional constipation, not exceeding seven days unless directed by a doctor.
  • Pregnancy and Breastfeeding: Use during these periods requires consultation with a health professional to weigh potential benefits against risk, as formal safety data is limited. The medication is classified as Pregnancy Category C.

Patients should immediately discontinue use and seek medical attention if they experience rectal bleeding or fail to have a bowel movement after treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Milax (Glycerol Suppository) is a highly localized osmotic laxative, and official regulatory documentation reflects this by noting that systemic drug-drug interactions are not expected.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Other Rectal Preparations (e.g., enemas, other suppositories)
Mechanistic basis of interactions Local Pharmacodynamic Interference; no documented systemic pharmacokinetic effects (e.g., CYP or transporter effects) due to minimal absorption.
Timing-based interaction rules Administration must be separated by 2 to 4 hours from other rectal preparations.
Population-specific interaction notes Diabetic Patients: Use may interfere with blood glucose control (a physiological caution).

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification No Expected Systemic Interaction Risk (for drug-drug interactions). Use with Caution for co-administration with other rectal preparations or in diabetic populations.

Official Interaction Statements

The documented risks are limited to local and physiological interactions, as specified by regulatory authorities. Co-administration with other rectal preparations is associated with a risk of local interference or reduced efficacy, mandating a timing-based separation rule. The use of this product also requires a caution for diabetic patients due to the potential to affect the regulation of blood glucose.

This structure confirms that official regulatory documents define the interaction profile based on poor systemic absorption and local effects, with the main constraint being the need to separate administration from other local products.

Mechanism of Action

How Milax Works

Milax's mechanism of action is primarily localized and physical, operating entirely within the lower bowel and initiating a predictable reflex arc activation; it does not rely on systemic absorption or modulation of central nervous system pathways.


Targeted Modulation of Rectal Fluid Dynamics

The active ingredient, Glycerol, exerts a significant hyperosmotic effect upon delivery. This mechanism involves establishing a physical gradient in the rectal lumen, drawing free water from the surrounding capillary beds and tissues into the lower bowel. This key movement of fluid acts directly to increase the fluid content and lubricity of the intestinal contents.


Mechanical Initiation of the Defecation Reflex

The influx of water resulting from the osmotic action causes the contents of the rectum to expand, leading to a rapid and distinct mechanical distention of the rectal wall. This distention stimulates local stretch receptors, which are the biological targets that activate the body's intrinsic defecation reflex arc. This neuro-muscular reflex initiates reflex peristalsis (propulsive smooth muscle contraction), which provides the propulsive smooth muscle contraction in the distal bowel.

Dosage and Administration Information

Administration and Dosing Instructions (Adults)

Polyethylene glycol 3350 powder (commonly referred to by the brand name MiraLAX), is administered orally as a solution. Preparation and dosing follow a uniform schedule for adults and adolescents aged 17 years and older, with a self-treatment duration limit.

Official Dosing Schedule

The standard, once-daily dose for individuals 17 years of age and older is 17 grams of the powder, measured using the fill-line on the bottle cap (top of the white section) or one pre-measured packet.

Administration Scope Detail
Route of Administration Oral
Dosing Schedule 17 grams once daily
Age Group Rule Adults and children 17 years; children 16 years must consult a doctor.
Duration Constraint Do not use for more than 7 days, unless directed by a doctor.

Preparation and Procedural Steps

To ensure proper use, the powder must be fully dissolved before consumption. The procedural steps are as follows:

  1. Measure 17 grams of powder (fill bottle cap to the top of the white section or use one packet).
  2. Stir and dissolve the powder into any 4 to 8 ounces of beverage (cold, hot, or room temperature).
  3. Consume the solution immediately after the powder is completely dissolved. Do not drink if clumps remain.
  4. Do not combine the powder with starch-based thickeners, such as those used for difficulty swallowing.

Missed Dose and Special Conditions

Administration is independent of meals and may be taken at any time of day. The daily dose should not be exceeded and use should not continue beyond one week without medical consultation. No specific instruction for a missed dose is explicitly provided; therefore, individuals are advised to follow the once-daily frequency.

Recent Clinical Evidence

Research evidence / Overview of Studies for Milax

The available research evidence for Milax (Glycerol Suppository) comes from a combination of clinical trials, observational data gathered over decades of use, and systematic reviews that synthesize the findings for specific patient groups. This information contributes to the broader evidence landscape and describes group patterns, but research does not determine whether an individual will respond similarly.

Evidence for Occasional and Acute Constipation Relief

The primary evidence base for research exploring this agent in situations involving acute, occasional constipation is constituted by regulatory records and various short-term clinical studies. These studies were conducted during research scenarios observing responses over defined time intervals in the general adult and pediatric populations (aged 2 years and older).

Researchers in these trials primarily focused on monitoring outcomes related to physical discomfort, such as the time interval from administration to the first observed stool passage. Studies focusing on conditions associated with acute or disruptive episodes typically described short-term patterns in symptoms that were measured in the observed populations.

Studies in Specific Patient Groups

Research exploring the use of glycerol suppositories was studied for the pediatric population (children aged 2 years and older). Findings from studies in these younger patient groups often focus on acute symptom patterns and are applied in studies examining how symptoms change over time.

For older adults, evidence describing the use of these agents was studied for outcomes related to daily functioning, often derived from observational settings. This evidence highlights what has been observed so far in managing conditions marked by functional limitations, though this research does not determine whether an individual will respond similarly.

Research Focus on Long-Term Outcomes and Follow-up

The research conducted on this product has generally explored outcomes linked to the acute constipation event. As a result, follow-up durations were limited in many instances.

Because trials often focus on episodes where symptoms become more noticeable, there is limited information for long-term outcomes concerning sustained use or patterns of use for chronic constipation. Research does not provide extensive insight into the outcomes of using this type of localized agent continuously over extended periods.

Areas of Limited or Inconclusive Research

Comparative evidence is lacking in contemporary, large-scale studies when Milax is directly compared to some newer, orally administered osmotic agents for the assessment of an acute event.

Furthermore, in highly specialized populations, such as preterm or low-birth-weight infants, research has examined the use of glycerol to examine the time required to reach full feeding tolerance and other outcomes. However, a synthesis of these trials shows the findings were mixed regarding the study outcomes, and the overall certainty remains low.

Key Studies & References

  1. Glycerin Suppositories - DailyMed (Human OTC Drug Label)
  2. Management of Constipation in Adult Patients: Acute and Chronic Treatment Pathways (NHS Guidelines)

Frequently Asked Questions (FAQ)

Common questions about Milax (FAQ)

Q: How does Milax differ from other similar medications?

A: Milax is officially classified as a highly localized, osmotic laxative. It uses the active ingredient Glycerol, which works by drawing water into the lower bowel to soften stool. This mechanism is different from that of stimulant laxatives, which directly promote nerve-mediated bowel movements.


Q: What is the difference between Milax and an over-the-counter medicine?

A: Milax is, in fact, classified by regulatory authorities as an Over-the-Counter (OTC) medicine. This classification means the medicine is deemed safe and effective for the temporary self-management of minor conditions without requiring a prescription from a health professional.


Q: Does Milax cause drowsiness or affect my ability to drive?

A: Official product information, such as the Summary of Product Characteristics, commonly indicates that no effects on the ability to drive or operate machinery are expected with this medicine. The product's action is localized to the lower bowel and is not expected to affect the central nervous system.


Q: Is it safe to take Milax with vitamins or herbal supplements?

A: Regulatory documents focused on drug interactions for this product generally state that no systemic interactions are expected. They primarily caution only about separating its administration from other rectal preparations. The product labeling generally recommends that all current medications and supplements be discussed with a health professional.


Q: How long does it typically take for Milax to start working?

A: Regulatory information indicates that the product typically produces an effect within a short time frame, which is often described as 15 minutes to one hour after administration. Individual responses may vary.


Q: Does Milax have any known food interactions?

A: Official regulatory documents, such as the Summary of Product Characteristics, state that no known food interactions are expected. As a localized rectal suppository, systemic food interactions are generally not expected to occur.


Q: Is there a generic version of Milax available?

A: Yes, the active ingredient, Glycerol, is widely available in generic and store-brand rectal suppository formulations. Official references often list the product alongside its commonly available generic versions.


Q: Can Milax be crushed or split if a person has trouble swallowing?

A: Milax is manufactured as a rectal suppository, not an oral tablet or capsule, and is not designed to be swallowed. Crushing or splitting the suppository is not part of the administration procedure and may compromise its intended localized effect.


Q: Are there any specific lifestyle changes recommended while taking Milax?

A: Official regulatory labels do not prescribe lifestyle changes. However, health professionals often recommend general non-pharmacological measures, such as maintaining adequate dietary fiber and fluid intake, as standard management for occasional constipation.


Q: What happens if I stop taking Milax suddenly?

A: For the short-term use intended for occasional constipation, regulatory warnings do not indicate specific concerns about stopping the product suddenly. Warnings about potential issues are associated only with using the product too often or for a prolonged period, which can lead to laxative dependence.


Q: Does Milax affect blood pressure or heart rate?

A: Officially listed adverse effects for this product focus on localized gastrointestinal issues, such as rectal irritation or abdominal discomfort. Effects on systemic functions like blood pressure or heart rate are not typically included in the official safety profile for this localized medicine.


Q: Can I drink alcohol while I am taking Milax?

A: Official interaction sections of regulatory documents commonly state that no interactions with alcohol are listed. Alcohol interactions are generally not noted as a constraint for this localized osmotic laxative.


Q: Does Milax interact with birth control pills?

A: The official interaction profile is generally limited to local, physical interference with other rectal preparations. Systemic drug-drug interactions are generally not expected. As a result, no specific interaction with oral contraceptives is typically listed in official regulatory documents.


Q: Does Milax affect sleep patterns?

A: Sleep pattern changes are not listed among the officially documented adverse effects for this product. The listed effects are primarily localized gastrointestinal discomfort and irritation.


Q: Is Milax considered a controlled substance?

A: No. The product is officially classified as an Over-the-Counter (OTC) osmotic laxative and is not listed as a controlled substance by major regulatory authorities.


Q: Do official sources describe how quickly Milax leaves the body?

A: Official pharmacokinetic information indicates that the active ingredient, Glycerol, is poorly absorbed following rectal administration. Because the action is localized, systemic absorption into the bloodstream is considered minimal or negligible.


Q: Is it possible to develop a tolerance to the effects of Milax?

A: Official safety warnings indicate a risk of developing tolerance or dependence. This occurs only if the product is used too often or for a prolonged period that extends beyond the recommended short-term use for occasional constipation.


Q: Does Milax affect appetite or weight?

A: Officially listed adverse effects do not include changes in appetite or weight as common side effects. Changes in weight are not listed as an expected side effect when the product is used for short periods.


Q: Are there any known issues with taking Milax before or after surgery?

A: The regulatory label does not include a specific general warning about surgery. However, this class of product is sometimes used under medical guidance as part of bowel preparation protocols before certain surgical procedures.


Q: Is it common for the effect of Milax to fade over time?

A: The risk of the effect fading or diminishing over time (tolerance) is noted in regulatory warnings. This warning applies specifically to the product being used excessively or for periods longer than the recommended one week for occasional constipation.


Q: Does Milax interact with common cold or flu medications?

A: Official interaction sections generally state that systemic drug-drug interactions are not expected. The primary constraints noted in official documents relate to co-administration with other rectal preparations and caution for diabetic patients.


Q: Are there any known long-term side effects that appear years later?

A: The product is officially intended for short-term use for occasional constipation. Regulatory profiles do not typically list specific side effects that appear years later, and research on long-term outcomes for sustained use is generally limited.


Q: Do official patient information leaflets give clear warnings about driving?

A: Patient information leaflets often reflect the Summary of Product Characteristics, which commonly states that no effects on the ability to drive and use machines are expected for this medicine.


Q: How is the effectiveness of Milax measured in clinical trials?

A: Clinical trials and regulatory data supporting the use of this product often measure effectiveness by monitoring the primary outcome of the time interval between administration and the first observed stool passage.


Q: Is Milax approved in other countries, and for the same uses?

A: The active ingredient, Glycerol, is approved and used globally by numerous regulatory bodies, including those in Europe and Australia. It is typically approved for the same primary use: the relief of occasional constipation.


Q: What kind of studies support the use of Milax for its main indication?

A: Evidence supporting the use of this product for occasional constipation relief is primarily derived from short-term clinical studies and observational data. These studies focus on immediate outcomes like the time required for the first bowel movement.

How should Milax be stored and disposed of?

How to Store and Dispose of Milax (Glycerol Suppository)

The official labeling mandates specific conditions for storing glycerol suppositories to maintain their stability and integrity.

Storage Requirements

The product must be stored at controlled room temperature, specifically within the range of 15 C to 30 C (59 F to 86 F). Storage areas must be dry, and the product must be kept away from excessive heat, which means avoiding storage in damp areas like a bathroom or near a sink. The suppositories must remain in their original pack or blister and the container must be tightly closed to protect the contents.

Safety and Disposal

It is a mandatory safety instruction that the medicine must be kept out of reach of children. The suppositories should not be used after the expiration date printed on the packaging. For disposal of any unused or expired product, individuals are instructed to consult a pharmacist or return it to a pharmacist for proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Milax found in:

A-Z Index: